普罗帕酮治疗川崎病合并心律失常临床观察

Clinical Observation of Propafenone for Treating Kawasaki Disease Complicated with Arrhythmia

目的观察普罗帕酮治疗川崎病合并心律失常的疗效及安全性。方法随机抽取医院收治的川崎病合并心律失常患儿78例,按随机数字表法分为观察组与对照组,各39例。对照组患儿给予美托洛尔治疗,观察组患儿给予普罗帕酮治疗。比较两组患儿临床疗效及不良反应发生情况。结果观察组的总有效率为94.87%,明显高于对照组的74.36%(P<0.05);观察组患儿的心功能、C反应蛋白与肌钙蛋白等指标改善幅度均明显大于对照组(P<0.05);观察组不良反应发生率为10.26%,明显低于对照组的30.77%(P<0.05)。结论普罗帕酮治疗川崎病合并心律失常临床效果显著,安全可靠,值得临床推广。

Objective To observe the clinical efficacy and safety of Propafenone in the treatment of Kawasaki disease complicated with arrhythmia. Methods Totally 78 children with Kawasaki disease complicated with arrhythmia admitted to our hospital were randomly selected and divided into the observation group and control group,39 cases in each group. The control group was treated with Metoprolol, while the observation group was treated with Propafenone. The clinical efficacy and the adverse drug reactions were compared in the two groups. Results The total effective rate of the observation group was 94. 87%,which was significantly higher than 74. 36% of the control group（P 〈 0. 05）,the improvement of cardiac function,C reactive protein and troponin in the observation group was significantly higher than those in the control group （P 〈 0. 05）,the incidence rate of adverse reactions in the observation group was 10. 26%, which was significantly lower than 30. 77% in the control group （P 〈 0. 05）. Conclusion Propafenone in the treatment of Kawasaki disease complicated with arrhythmia has good effect and safety,which is worthy of clinical promotion.